The efficacy of combination therapy of toltrodine and tamsulosin on urinary symptoms

The comparison of the Efficacy and Safety of Combination of Tamsulosin with Tolterodin and Tamsulosin alone In the Treatment of Double-J Stent Related Urinary Tract Symptoms

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190119042410N1

Enrollment

Registered

2020-07-05

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary symptoms caused by stent.

Interventions

Intervention 1: Intervention group 1 Tamsulosin 0.4 mg daily for 2 weeks. Intervention 2: Intervention group 2 Tamsulosin 0.4 mg daily for 2 weeks and Toltrodine 2 mg daily for 2 weeks.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years of age Completion of written consent form One-way ureteral stenting after ureteroscopy and TUL for ureteral stones Negative urine culture prior to TUL and stents male

Exclusion criteria

Exclusion criteria: Physician diagnosed sensitivity to tamsulosin, toltrodine or folic acid Establishment of ureteral stent during the last 6 months

Design outcomes

Primary

Measure	Time frame
Score from the USSQ Questionnaire. Timepoint: Start studying and two weeks later. Method of measurement: USSQ Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarshad zohrabi

Boushehr University of Medical Sciences

zohrabi.fsh@gmail.com+98 77 3332 0657

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026